Dr. Josh Evans, a Loyola Internal Medicine physician, with WJOL radio
Dr. Joshua Evans, a Primary Care physician, chose this field of medicine because he wanted to build long-term relationships with his patients. He talks about...
By: Loyola University Health System
Go here to see the original:
Dr. Josh Evans, a Loyola Internal Medicine physician, with WJOL radio - Video
Prof. Lord Robert Winston - Medicine, Ethics and Society
Professor Lord Robert Winston delivers an Enlightenment Lecture entitled "Medicine, Ethics and Society". This lecture also forms part of this year #39;s Our Chan...
By: EdinburghUniversity
Excerpt from:
Prof. Lord Robert Winston - Medicine, Ethics and Society - Video
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation Medicine, Inc. (FMI) today announced that the discovery of a novel and potentially clinically actionable oncogenic gene fusion in lung cancer, NTRK1, using FoundationOne, was published in the current online edition of Nature Medicine1. Lung cancer remains the leading cause of cancer-related death in men and women in the United States2; however, the use of targeted therapies in lung cancer has led to significant clinical benefit for patients with EGFR mutations and ALK fusions. Therefore, the identification of new, drug-sensitive oncogenes in this disease is of great clinical interest and has the potential to expand treatment options for patients.
Our understanding of cancer complexity is increasing, and lung cancer continues to be dissected into a series of uncommon or even rare diseases based on the molecular alterations driving a patients individual cancer, stated Vincent Miller, M.D., chief medical officer at Foundation Medicine and co-author of the study. By discovering a new and potentially clinically actionable gene fusion in lung cancer, we believe this is an opportunity to explore new and different treatment options for patients harboring this fusion. Based on these findings, we believe clinical studies of selective TRK inhibitors in NTRK1 rearranged non-small cell lung cancer are warranted.
Michael J. Pellini, M.D., president and chief executive officer at Foundation Medicine added, In addition to making important contributions to cancer patient care, the discovery of novel gene markers using FoundationOne is an excellent example of how clinical and commercial progress can coincide, especially in collaboration with academic investigators. These discoveries drive the evolution of FoundationOne, support new and ongoing collaborations with our pharma partners, and provide further evidence that our comprehensive approach yields high clinical utility.
In an effort to identify additional potential oncogenes in lung cancer, Foundation Medicine and its collaborators, the University of Colorado Cancer Center and Dana-Farber Cancer Institute, used FoundationOne to assess cancer-related genes on tumor samples from 36 patients negative for activating alterations in EGFR, KRAS, ALK, and ROS1 using standard clinical assays. Researchers identified novel gene fusions harboring the kinase domain of the NTRK1 gene that encodes the TRKA receptor. Both the MPRIP-NTRK1 and CD74-NTRK1 fusions demonstrated constitutive TRKA kinase activity. Preclinical data show that treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701, and crizotinib) inhibited tumor growth. In the study, one patient harboring the MPRIP-NTRK1 fusion demonstrated a minor radiographic response to crizotinib. Three of 91 patients (3.3%) without known oncogenic alterations profiled by FoundationOne harbored an NTRK1 gene fusion. These results suggest that NTRK1 gene fusions are a new oncogenic alteration in lung cancer and TRK inhibitors should be evaluated in clinical trials in patients harboring this gene fusion.
Following the recent publication of our analytic validation study of FoundationOne, the identification of NTRK1 further supports the clinical utility of comprehensive next-generation sequencing as a method to discover novel drug sensitive genomic alterations that would not otherwise be tested for or identified using currently available diagnostic approaches, commented Phil Stephens, Ph.D., vice president, cancer genomics at Foundation Medicine. Additionally, the preclinical data and preliminary clinical data on patient response to TRK inhibitor therapy informed by FoundationOne are very encouraging for further clinical investigation of TRK inhibitors in this patient population.
Foundation Medicine last week announced that results from a 24-month, multi-institution collaboration demonstrating the analytic validation of its cancer genomic profiling assay, FoundationOne, were published in the online edition of Nature Biotechnology3. This publication is the first to apply and extend the guidelines established by the Next-Generation Sequencing: Standardization of Clinical Testing (Nex-StoCT) workgroup to validate a clinical sequencing-based assay for cancer, therefore setting the standard for validation of targeted NGS in cancer.
About Foundation Medicine
Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicineis a registered trademark, and FoundationOneis a trademark of Foundation Medicine, Inc.
Read more:
M13 - HTC - Chinese Medicine - Oct 22nd Update
Tour Taiwan with me: http://hobbicide.com/M13Taiwan/ My Facebook: https://www.facebook.com/Mordeth13 MY CAMERA: http://tiny.cc/o9ttiw My...
By: M13
Read the original:
Focus on Regenerative Medicine
http://www.ihealthtube.com http://www.facebook.com/ihealthtube Dr. Joel Baumgartner describes his philosophy behind his practice and how it may be different ...
By: iHealthTube.com
Follow this link:
The Making of Stony Brook Medicine #39;s "Pink Glove Video"
Stony Brook unites to fight breast cancer.
By: sbcomm
The rest is here:
The Making of Stony Brook Medicine's "Pink Glove Video" - Video
Science Behind the Medicine and Medical Advances: Evolving Trends in Hip and Knee Arthroplasty
We will explore the discoveries of Vanderbilt #39;s biomedical and engineering labs. Some of these discoveries we may see in our doctors #39; offices very soon. Expe...
By: VanderbiltUniversity
More:
FREIKORPS - MEDICINE MAN LIVE DIXON HALLS GLASGOW 04 12 1987
By: john harrison
Visit link:
FREIKORPS - MEDICINE MAN LIVE DIXON HALLS GLASGOW 04 12 1987 - Video
ASSERT - School of Medicine, University College Cork
The ASSERT (Application of Science to Simulation, Education and Research on Training for Health Professionals) for Health Centre is a state-of-the-art, simul...
By: UCCIreland
Read the original post:
ASSERT - School of Medicine, University College Cork - Video
PHILADELPHIA Penn Medicine was recognized with two Gold Excellence awards by the International Economic Development Council (IEDC) for its efforts to create positive change in the community. Penn Medicine was honored for its work redeveloping Philadelphias former Civic Center into a matrix of world-class medical research and treatment centers. The award included the Philadelphia Industrial Development Corporation (PIDC), who owned the land, as well as the Childrens Hospital of Philadelphia (CHOP), which has also built in the area.
The two honors, in the categories of Public Private Partnerships for communities with populations greater than 500,000, and Partnerships with Educational Institutions for communities with populations greater than 500,000, were presented at an awards ceremony earlier this month at the IEDC Annual Conference in Philadelphia. The non-profit IEDC is a membership organization serving economic developers. Its Excellence in Economic Development Awards recognize the worlds best economic development programs and partnerships, marketing materials, and the years most influential leaders.
The former Civic Center site now houses Penn Medicines Perelman Center for Advanced Medicine, the Smilow Center for Translational Research, and the Roberts Proton Therapy Center, all of which have taken shape since 2005. The area is also the site of the Colket Translational Research Building and the Buerger Center for Advanced Pediatric Care, slated to open in 2015.
Together, Penn Medicine and CHOP invested more than $2 billion in its facilities on the site, and construction on another one millionsquare feet of space isexpected to finish by 2015.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and theUniversity of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals byU.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided$827million to benefit our community.
See the original post here:
MOUNTAIN VIEW, Calif. & HOUSTON--(BUSINESS WIRE)--
The Human Genome Sequencing Center (HGSC) at Baylor College of Medicine and DNAnexus today announced a broad collaboration focused on advancing the state-of-the-art in the large-scale clinical analysis of genomic data. Through this collaboration, the HGSC has adopted the DNAnexus enterprise cloud platform to power its Mercury pipeline, a semi-automated and modular set of tools for the analysis of next-generation sequencing data in both research and clinical contexts. The collaborators also worked with Amazon Web Services (AWS) to process data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium using the Mercury pipeline, generating 430TB of results and making them available to hundreds of researchers participating in this global project.
The HGSCs Mercury pipeline identifies mutations from genomic data, setting the stage for determining the significance of these mutations as a cause of serious disease and is used as the core variant-calling pipeline for the CHARGE Consortium. The CHARGE Consortium is aimed at better understanding how human genetics contributes to heart disease and aging. The CHARGE Consortium has a longstanding collaboration with the HGSC to fuel disease gene discovery. These discoveries are instrumental in understanding disease and aging in mechanistic detail, enabling the development of new medical interventions and analysis tools.
The management and analysis of genomes at the scale needed to appropriately power clinical studies requires computational infrastructure that exceeds the capacity of most institutional resources, said Jeffrey Reid, Ph.D., Assistant Professor, Department of Molecular and Human Genetics, Baylor College of Medicine. Working with DNAnexus and Amazon Web Services, we were able to rapidly deploy a cloud-based solution that allows us to scale up our support to researchers at the HGSC, and make our Mercury pipeline analysis data accessible to the CHARGE Consortium, enabling what will be the largest genomic analysis project to have ever taken place in the cloud.
The CHARGE project involves more than 300 researchers across five institutions around the world analyzing the genome sequence data of over 14,000 individuals (3,751 whole genomes and 10,771 exomes), requiring approximately 2.4 million core-hours of computational time and some 860 TB of storage. At the projects peak, HGSC used the DNAnexus platform to spin up more than 20,000 cores on-demand in order to run the CHARGE data through the Mercury analysis pipeline. During this period, HGSC was running the largest genomics analysis cluster in the world, hosted by AWS.
Many large-scale population studies to date have been limited in scope by a lack of the necessary compute power; this is a real hindrance in realizing the full promise of genomic medicine, said Richard Daly, CEO of DNAnexus. The DNAnexus platform offers research and clinical enterprises the requisite computational resources that allow them to focus on the data and provide the ability to share and collaborate in a secure compliant environment. Through this collaboration with the HGSC and Amazon Web Services, 300 scientists can now perform downstream analyses on these invaluable health and aging data at a scale not previously possible.
DNAnexus provides an enterprise-focused API-based platform-as-a-service that enables clinical and research enterprises to efficiently move their analysis pipelines into the cloud, using their own algorithms alongside industry-recognized tools and reference resources to create customized workflows in a secure, cost-effective and compliant environment. With DNAnexus, labs of any size can build and run their data analysis applications and workflows from anywhere in the world, and work securely with research and clinical collaborators.
For more information please visit: https://dnanexus.com/usecases-charge.
About the Human Genome Sequencing Center at Baylor College of Medicine, (HGSC)
As one of three U.S. Centers that contributed to the Human Genome Project, the HGSC played a pivotal role in the emergence of genomics as a core discipline in modern biomedical and translational research, and has been at the forefront of technical innovation and testing of next-generation sequencing technologies. The HGSC is also a leader in developing large-scale sequencing and analysis solutions, and has emerged as a world leader in the analysis of personal genomes and the introduction of genomics into medicine. For more information please visit:https://www.hgsc.bcm.edu.
See original here:
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/pvcsvz/global) has announced the addition of the "Worldwide Personalized Medicine Diagnostics Industry to 2016" report to their offering.
The report, the Global Personalized Medicine Diagnostics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Personalized Medicine Diagnostics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries.
The key vendors dominating this space include:
Key segments:
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Introduction
Follow this link:
Research and Markets: Worldwide Personalized Medicine Diagnostics Industry to 2016
BOCA RATON, Fla.--(BUSINESS WIRE)--
Modernizing Medicine, Inc., announced it is ranked number 34 for medium-sized businesses on Modern Healthcare magazines top 100 Best Places to Work in Healthcare list. The industry's leading source of healthcare business and policy news for healthcare professionals, Modern Healthcare magazine chose winners based the results of an employee engagement and satisfaction survey, which gauges overall employee satisfaction in regards to standard benefits, best practices and more.
Teamwork is in our DNA, said Daniel Cane, President and CEO of Modernizing Medicine. Our success would not have been possible without the hard work of our passionate, innovative team that is committed to building something better for the healthcare industry and having fun doing it. We are thrilled to receive this award and we look forward to another exciting year of growth at this company where people love to come to work every day.
The recognition program, now in its sixth year, honors outstanding employers in the healthcare industry on a national level. Specifically, the award recognizes workplaces in healthcare that enable employees to perform at their optimum level, providing patients and customers with the best possible care, products and services. Winners were honored yesterday at a conference and awards gala at the Hyatt Regency in Atlanta, Ga., and are listed on the Modern Healthcare website.
For more information about the Modern Healthcare Best Places to Work Awards, please visit http://www.modernhealthcare.com/section/bestplaces-2013. The Modernizing Medicine team continues to grow! For more information about careers at Modernizing Medicine please visit http://www.modmed.com/careers.
About Modernizing Medicine Modernizing Medicine is transforming how healthcare information is created, consumed and utilized in order to increase efficiency and improve outcomes. Our product, Electronic Medical Assistant (EMA), is a cloud-based, specialty-specific electronic medical record (EMR) system with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each providers unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, orthopedics, otolaryngology and plastic and cosmetic surgery markets, and to more than 1,300 physician practices across the country. In 2013 Modernizing Medicine was listed on Forbes annual ranking of Americas Most Promising Companies.
View post:
Modernizing Medicine Named Among Top 100 Best Places to Work in Healthcare
BMC Medicine - Editorial Board Members discuss Open Access publishing
In recognition of Open Access week, we asked some BMC Medicine Editorial Board Members to share their views and experiences on open access publishing. In thi...
By: BioMedCentral
Read more:
BMC Medicine - Editorial Board Members discuss Open Access publishing - Video
by Regina Mobley, 13News Now
WVEC.com
Posted on October 24, 2013 at 5:13 PM
NORFOLK -- Reproductive medicine in America changed forever onDecember 28, 1981 when Drs. Howard andGeorgeanna Jones announced the birth ofElizabeth Carrat Norfolk General Hospital.
Elizabeth was the nation's first, so-called "test tube baby." The birth was controversial at the time. Some even called in vitro fertilization, the process by which an egg is fertilized by sperm outside the body, as immoral.
When Dr. Georgeanna Jones died in 2005, the controversy had faded and the Joneses had become the "grandparents" to thousands ofIVFbabies.
While Dr.Howard Jones is known as the co-founder of in vitro fertilization in America, he also played a major role in another historic, yet alsocontroversial, advance in medicine.
At Johns HopkinsHospital in Baltimore, Maryland in 1951, Dr. Jones examined married mother of five Henrietta Lacks, who had complaints of cervical pain. Suspecting cervical cancer,Dr. Jones removed tissue from the cervix that was used for a biopsy.
After 62 years, Dr. Jones says he still vividly remembers the examination. "It did not look like any cancerI had ever seen, and at that timeI had seenmaybe a thousand cancers of the cervix," said Jones.
The cancer diagnosiswas confirmed, and within the year, the disease claimed the life of the 31-year oldmother.
Original post:
Father of in vitro fertilization weighs in on future of reproductive medicine
BOCA RATON, Fla.--(BUSINESS WIRE)--
Modernizing Medicine, Inc., announced today that it is a winner of a 2013 Inc. Hire Power Award, recognizing private companies that are restoring lives and rebuilding the economy by putting Americans back to work. Modernizing Medicine was chosen based on the number of jobs added over the past three years and is ranked #14 in the health industry.
This is such an important award and we feel honored and validated to be named among the companies who are leading the way in American job creation, said Daniel Cane, President and CEO of Modernizing Medicine. I truly believe that we have formed a team of the best and brightest in both technology and medicine, and awards like this serve as a reminder of the excellent work our team is doing to improve physician workflow and ultimately patient health.
For the second year in a row, we are pleased to recognize the employers who are putting Americans back to work for a second time, says Eric Schurenberg, Editor-in-Chief of Inc. The Hire Power Awards are the only awards that single out job creators. We think its fitting to pay tribute to company founders not just for their business prowess but also for their immense contribution to the welfare of U.S. workers and the vitality of the U.S. economy.
Now in their second year, the Hire Power Awards have garnered significant attention, shining a light on the crucial role private businesses play in creating jobs and supporting the country's economic vitality.
Winners are recognized on the Inc. website and will be recognized in the November issue of Inc. Magazine, which will have a special feature on the 2013 Hire Power Awards. Inc. and Bank of America Merrill Lynch will also honor winners at an awards ceremony at the Marines' Memorial Club & Hotel in San Francisco, California on November 12.
For more information about the Inc. Hire Power Awards, please visit http://www.inc.com/hire-power. The Modernizing Medicine team continues to grow. For more information about careers at Modernizing Medicine please visit http://www.modmed.com/careers.
About Modernizing Medicine
Modernizing Medicine is transforming how healthcare information is created, consumed and utilized in order to increase efficiency and improve outcomes. Our product, Electronic Medical Assistant (EMA), is a cloud-based, specialty-specific electronic medical record (EMR) system with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each providers unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, orthopedics, otolaryngology and plastic and cosmetic surgery markets, and to more than 1,300 physician practices across the country. In 2013 Modernizing Medicine was listed on Forbes annual ranking of Americas Most Promising Companies.
Follow this link:
The string band Old Crow Medicine Show was invited to become a member of a rather exclusive club in August: The Grand Ole Opry. "There always seems to be these dream moments in a country music life like when Merle Haggard whispers something in your ear," lead singer Ketch Secor tells Billboard. "Our lives have been full of these moments where you cant really believe they are happening."
To keep the word from leaking out, Opry brass decided to bestow the invitation far away from Music City. "It happened in Cleveland, so I think that helped us to be clearly confused when Marty Stuart appeared on stage. We had been led to believe that something else was happening with the Rock & Roll Hall of Fame that night. We had been deceived by our manager, and everyone fell for it."
The band was officially inducted as Opry members on September 17, and Secor says they can definitely feel a difference being a member of the country music institution as opposed to being a guest.
"We look up and down the hallways backstage a little differently. We saw Little Jimmy Dickens, whom weve seen and spoken to a number of times. But, now we were a part of the family. It was a powerful feeling. Ive met Jeannie Seely before, but her welcome into the family was something that never happened before. Being such an avid listener of the Opry for fifteen years, Ive really come to know who the old guard is. They all came out to welcome us out, like George Hamilton IV."
Darius Rucker whom the Old Crow Medicine Show replaced as the most recent inductee into the Opry figures into the bands success story as well as Secors this year. It was through their record that Rucker became reacquainted with the classic "Wagon Wheel," prompting him to record the tune. It became not only a top record but also earned an nomination for Song of the Year at the upcoming 46th Annual Country Music Association Awards meaning that Secor shares the nomination with the legendary Bob Dylan. Dylan penned the chorus and melody during the sessions for Pat Garrett and Billy The Kid. Never commercially released by Dylan, Secor landed a copy of the bootleg of the unfinished sketch, and penned the verses. How does it feel to be included in the category with one of Americas most respected lyricists?
"It made me think a lot about Bob Dylan as a country singer a country music pioneer," he says. "He grew up listening to Roy Acuff. When you hear his records, you hear Hank Williams. You hear a lot of Roy. He credits Wayne Raney as his harmonica inspiration. These are country music makers. I think that Bob has more to do with country music than anyone in country music is willing to take note of. I think 'Lay Lady Lay is one of the ten greatest country songs ever sung. Im real excited that hes nominated, as much as myself. Im just glad that hes being recognized by the music industry that is so hugely indebted to his talent over the past half-century."
The Old Crow Medicine Show is busy in the studio working on a new project due out in 2014. As Opry members, Secor says the pressure is on. But, they wouldnt have it any other way.
"Theres something different when it comes to being in the recording studio. Everything has a longer shelf life. I just feels like theres more of a legacy at stake with to the music that we make when it comes to being Opry members. Its been exciting to make a record where you know that in addition to our fans who will enjoy it, theres a whole lot of other new fans that havent heard us yet that will dig it too."
See the article here:
Old Crow Medicine Singer Talks Opry, Sharing a CMA Nomination With Bob Dylan
Life as a family medicine resident: Methodist
Meet Sean, a family medicine resident at Methodist Hospital. He didn #39;t take the typical route to family medicine, but Sean #39;s really glad he chose the special...
By: UMN Health
Read more here:
At least 1,300 applicants from around the world have applied for one of six spots in the inaugural class of Billings Clinics Internal Medicine Residency Program, which is designed to train primary-care physicians.
About 200 of the applicants are U.S. graduates; the balance are from all corners of the globe.
Only 100 or so candidates will be invited to interview on the Billings Clinic campus. The grueling process began Tuesday and will continue into January.
In addition to the six internal medicine residency slots, four additional spots will be reserved for applicants who need only a one-year clinical base before going elsewhere to train in a specialty area such as radiology, ophthalmology, dermatology and anesthesiology.
The Internal Medicine Residency Program is the first of its kind in Montana and Wyoming. It was accredited earlier this year for three years by the Chicago-based Accreditation Council for Graduate Medical Education, the maximum length of time for an initial accreditation. It was one of only four internal-medicine residency programs in the country to achieve accreditation.
At full capacity, the residency program could be producing as many as six new doctors a year.
The hope is that those new doctors will choose to practice in Montana, where most counties have a shortage of primary-care physicians and 10 counties have no physician at all.
The program will open to the first class of students in July 2014.
Dr. RogerBush, program director, is pleased with the sizable number of applicants but not surprised.
With healthcare reform and the growth in the number of medical school graduates, theres a lot more demand for these types of physicians than there was a few years ago, Bush said. Ten years ago, not very many people considered general internal medicine or primary care, now it looks like its going to be much more popular.
See the rest here:
Billings Clinic draws worldwide interest in its Internal Medicine Residency Program